Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

XR-9051: MDR-reversing agent

June 14, 1996

Fujisawa reveals FR-177391, agent for cachexia in cancer patients

June 14, 1996

PN 27.1 compassionate use trial broadened

June 14, 1996

ZK-138723: Schering AG's aromatase inhibitor

June 14, 1996

RPR's Taxotere available in the U.S.

June 14, 1996

Navelbine on Canadian market

June 14, 1996

ISIS-5132/CGP-69846A efficacy reported in Nature Medicine

June 7, 1996

Indena claims colchicine derivatives

June 7, 1996

Manufacturing agreement for Neoprobe's RIGS/ACT activated cell therapy

June 7, 1996

Melanogenesis inhibitor revealed

June 7, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 12, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 12, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.